SCHEMBL3256465

SCHEMBL3256465

O=C(Cc1cnc(NS(=O)(=O)c2ccc(-c3ccc(OC(F)(F)F)cc3)cc2)s1)N1CCOCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 1/20 0.47
▸ LMNA P02545 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ HSD11B1 P28845 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ MMP1 P03956 1/20 0.42
▸ MMP2 P08253 1/20 0.42
▸ MMP9 P14780 1/20 0.42
▸ SCN3A Q9NY46 1/20 0.42
▸ PKM P14618 1/20 0.42
▸ OGA O60502 1/20 0.41
▸ EPHX2 P34913 1/20 0.40
▸ AKT1 P31749 1/20 0.40
▸ PIK3CA P42336 1/20 0.40
▸ MTOR P42345 1/20 0.40
▸ LIPC P11150 1/20 0.40
▸ LIPG Q9Y5X9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3253203 0.88 GAA (0.46) KMT2ALMNAGAAL3MBTL1HSD11B1
SCHEMBL3254312 0.86 MAPT (0.52) KMT2ALMNAGAAHSD11B1ALDH1A1
SCHEMBL3248621 0.86 KMT2A (0.49) KMT2ALMNAGAAHSD11B1ALDH1A1
SCHEMBL5830631 0.86 KMT2A (0.45) KMT2ALMNAGAAL3MBTL1ALDH1A1
SCHEMBL3253280 0.85 HSD11B1 (0.48) KMT2ALMNAGAAL3MBTL1HSD11B1
SCHEMBL3255832 0.85 HSD11B1 (0.52) KMT2ALMNAGAAL3MBTL1HSD11B1
SCHEMBL3248447 0.84 HSD11B1 (0.47) KMT2ALMNAGAAL3MBTL1HSD11B1
SCHEMBL5831281 0.84 KMT2A (0.45) KMT2ALMNAGAAL3MBTL1HSD11B1
SCHEMBL3256644 0.84 HSD11B1 (0.50) KMT2ALMNAGAAL3MBTL1HSD11B1
SCHEMBL3248435 0.84 SMN1; SMN2 (0.50) KMT2ALMNAGAAL3MBTL1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1461325-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-05-26 — — EP claimed
US-7671051-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2010-03-02 — — US claimed
US-20050250776-A1 Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 BIOVITRUM AB 2005-11-10 — — US claimed
WO-2004112782-A1 NEW USE V BIOVITRUM AB (SE) 2004-12-29 — — WO claimed
US-20030130318-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 — — US claimed
EP-1461325-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-05-26 — — EP disclosed
US-7671051-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2010-03-02 — — US disclosed
US-7094792-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-08-22 — — US disclosed
US-20050250776-A1 Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 BIOVITRUM AB 2005-11-10 — — US disclosed
US-20030130318-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250776-A1 Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 HSD11B1, HSD17B1, HSD17B11 KMT2A 3602/4885LMNA 3562/4885GAA 567/4885
US-20030130318-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 KMT2A 3247/4885LMNA 1976/4885GAA 351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback